HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that
Igor Gonda, PhD., Aradigm's President and CEO, will be a panel member at
the U.S. Food and Drug Administration's public workshop regarding the
design of clinical trials of antibacterial drugs for the treatment of
non-cystic fibrosis bronchiectasis at the Sheraton Silver Spring Hotel
in Silver Spring, MD on Friday, September 7, 2012 from 8:00 am to 3:30
pm Eastern time.
The public workshop is intended to provide information for and gain
perspective from health care providers, patients and patient advocacy
organizations, academia, and industry on various aspects of the design
of clinical trials.
A draft agenda for the workshop may be obtained on the FDA website at www.fda.gov.
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs delivered by inhalation for
the prevention and treatment of severe respiratory diseases by
pulmonologists. The Company has product candidates addressing the
treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and
anthrax infections, and prevention of respiratory and other diseases in
tobacco smokers through smoking cessation.
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media